EUVIMEDSkopri EUVIMED
MetaanalyseSystematische ÜbersichtOpen access · CC BY 4.0

Colchicine and cardiovascular events: An updated meta‐analysis of published randomized controlled trials

Sining Xie, Federica Galimberti, Elena Olmastroni, Alberico L Catapano, Manuela Casula

Journal of Internal Medicine · 2025-12 · 298 (6) · 711-717

DOI: 10.1111/joim.20107 ↗

At a glance

Metaanalyse in Journal of Internal Medicine, published online on 2025-07-07. Written by Sining Xie and 4 co-authors. Institution: Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy. Major MEDLINE topics: Colchicine, Cardiovascular Diseases. Cited 12 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY 4.0).

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Colchicine shows promise in reducing cardiovascular risk, but a recent study raised the question whether this is really the case. We conducted a meta‐analysis of randomized controlled trials (RCTs) to assess its impact on cardiovascular outcomes in secondary prevention.

Methods

We systematically searched major databases up to March 2025 for RCTs comparing colchicine to placebo over a treatment duration of ≥12 months, reporting major adverse cardiovascular events (MACEs). Both fixed‐ and random‐effects models were used to compute pooled risk ratios (RRs) and 95% confidence intervals.

Results

Six RCTs comprising 21,774 patients were included. Colchicine significantly reduced the risk of MACEs (RR 0.74 [0.60–0.92]) and specific components of primary outcome (myocardial infarction, RR 0.85 [0.73–0.98]; stroke, RR 0.79 [0.65–0.95]), with no significant effect on cardiac death and revascularization.

Conclusion

These results support the efficacy of low‐dose colchicine in reducing MACEs when added to standard care for at least 12 months.

Subjects

MeSH terms (MEDLINE)

ColchicineCardiovascular DiseasesHumansRandomized Controlled Trials as TopicSecondary PreventionMyocardial Infarction

Author keywords

cardiovascular preventioncolchicineinflammationmajor adverse cardiovascular eventsmeta‐analysis

Substances

Colchicine

Authors and institutions

  • Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
  • IRCCS MultiMedica, Sesto San Giovanni (MI), Italy.

Cite

APA

Xie, S., Galimberti, F., Olmastroni, E., Catapano, A. L., & Casula, M. (2025). Colchicine and cardiovascular events: An updated meta‐analysis of published randomized controlled trials. Journal of Internal Medicine, 298(6), 711-717. https://doi.org/10.1111/joim.20107

Vancouver

Xie S, Galimberti F, Olmastroni E, Catapano AL, Casula M. Colchicine and cardiovascular events: An updated meta‐analysis of published randomized controlled trials. Journal of Internal Medicine. 2025;298(6):711-717. doi:10.1111/joim.20107

BibTeX
@article{Xie2025,
  author = {Xie, Sining and Galimberti, Federica and Olmastroni, Elena and Catapano, Alberico L and Casula, Manuela},
  title = {Colchicine and cardiovascular events: An updated meta‐analysis of published randomized controlled trials},
  journal = {Journal of Internal Medicine},
  year = {2025},
  volume = {298},
  number = {6},
  pages = {711--717},
  doi = {10.1111/joim.20107}
}
Start for free →